AndreaBozzo/ceres-open-data-index huggingface dataset:
PISA. The effect of paracetamol (acetaminophen) and ibuprofen on body temperature in acute stroke: Protocol for a phase II double-blind randomised placebo-controlled trial [ISRCTN98608690]

Background
          During the first days after stroke, one to two fifths of the patients develop fever or subfebrile temperatures. Body temperature is a strong prognostic factor after stroke. Pharmacological reduction of temperature in patients with acute ischaemic stroke may improve their functional outcome. Previously, we studied the effect of high dose (6 g daily) and low dose (3 g daily) paracetamol (acetaminophen) in a randomised placebo-controlled trial of 75 patients with acute ischemic stroke. In the high-dose paracetamol group, mean body temperature at 12 and 24 hours after start of treatment was 0.4°C lower than in the placebo group. The effect of ibuprofen, another potent antipyretic drug, on body-core temperature in normothermic patients has not been studied.
        
        
          Aim
          The aim of the present trial is to study the effects of high-dose paracetamol and ibuprofen on body temperature in patients with acute ischaemic stroke, and to study the safety of these treatments.
        
        
          Design
          Seventy-five (3 × 25) patients with acute ischaemic stroke confined to the anterior circulation will be randomised to treatment with either: 400 mg ibuprofen, 1000 mg acetaminophen, or with placebo 6 times daily during 5 days. Body-temperatures will be measured with a rectal electronic thermometer at the start of treatment and after 24 hours. An infrared tympanic thermometer will be used to monitor body temperature at 2-hour intervals during the first 24 hours and at 12-hour intervals thereafter. The primary outcome measure will be rectal temperature at 24 hours after the start of treatment. The study results will be analysed on an intent-to-treat basis, but an on-treatment analysis will also be performed. No formal interim analysis will be carried out.
Compound 530179: 2-[2-Nitro-4-(trifluoromethyl)phenoxy]acetohydrazide

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-[[(4-methoxyphenyl)-trimethylsilyloxymethylidene]amino]acetate. Molecular Formula: C16H27NO4Si2. Molecular Weight: 353.56. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Wisconsin (WI)

This report presents estimates for measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Wisconsin for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
MeSH 2025 Update - Combine Report

<b>(Includes MeSH 2023 and 2024 changes)</b>  The MeSH 2025 Update - Combine Report lists new Entry Combinations.  These are cases where a new, precoordinated Descriptor has been created to replace an existing Descriptor / Qualifier combination.  <b>This report includes MeSH changes from previous years, starting from 2023.</b>
Synovial stromal cells from rheumatoid arthritis patients attract monocytes by producing MCP-1 and IL-8

Macrophages that accumulate in the synovium of rheumatoid arthritis patients play an important role in the pathogenesis of this inflammatory disease. However, the mechanism by which macrophages are attracted into the inflamed synovium and accumulate there has not been completely delineated. The results of this study show that rheumatoid arthritis synovial stromal cells produce the chemokines monocyte chemotactic protein-1 and IL-8, and these have the capacity to attract peripheral monocytes. These results suggest that one of the mechanisms by which macrophages accumulate in the inflamed synovium is by responding to the chemokines produced locally.
Compound 525581: N,N-Dimethyl-N'-(3-methylphenyl)-p-methylbenzamidine

Chemical compound data from PubChem database. IUPAC Name: N,N,4-trimethyl-N'-(3-methylphenyl)benzenecarboximidamide. Molecular Formula: C17H20N2. Molecular Weight: 252.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Hospital Cost Report Audited Data Print Image: 2014

This print image version of the Institutional Cost Report (ICR) has been audited by the DOH. is the Institutional Cost Report (ICR) is a uniform report completed by New York hospitals to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations, (Part 86-1.2), Article 28 hospitals are required to file financial and statistical data with DOH annually. The data filed is part of the ICR and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends. For more information, check out: http://www.health.ny.gov/facilities/hospital/index.htm
The effect of GABA receptor ligands in experimental spina bifida occulta

Background
          The pathophysiology behind spina bifida and other neural tube defects (NTDs) is unclear. Folic acid is one variable, but other factors remain. Studies suggest that substances active at the GABA receptor may produce NTDs. To test this hypothesis pregnant rats were exposed to either the GABA a agonist muscimol (1, 2 or 4 mg/kg), the GABA a antagonist bicuculline (.5, 1, or 2 mg/kg), the GABA b agonist baclofen (15, 30, 60 mg/kg), or the GABA b antagonist hydroxysaclofen (1, 3, or 5 mg/kg) during neural tube formation. Normal saline was used as a control and valproic acid (600 mg/kg) as a positive control. The embryos were analyzed for the presence of a spina bifida like NTD.
        
        
          Results
          After drug administration the pregnancies were allowed to proceed to the 21st day of gestation. Then embryos were removed and skeletons staining and cleared. Vertebral arch closure was measured. Results indicate that the GABAa receptor agonist muscimol, the GABAa receptor antagonist bicuculline, and the GABAb agonist baclofen produced NTDs characterized by widening of the vertebral arch. Oppositely the GABAb antagonist hydroxysaclofen produced narrowing of the vertebral arches.
        
        
          Conclusions
          The findings indicate that GABA a or b ligands are capable of altering neural formation. GABA may play a greater than appreciated role in neural tube formation and may be important in NTDs. The narrowing of the vertebral arch produced by the GABA b antagonist hydroxysalcofen suggests that GABA b receptor may play an undefined role in neural tube closure that differs from the GABA a receptor.
Compound 528893: Dipropylbarbituric acid M (OH), #1

Chemical compound data from PubChem database. IUPAC Name: 5-(1-hydroxypropyl)-5-propyl-1,3-diazinane-2,4,6-trione. Molecular Formula: C10H16N2O4. Molecular Weight: 228.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530245: Tetrahydrocannabinol, TMS

Chemical compound data from PubChem database. IUPAC Name: trimethyl-[(6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-yl)oxy]silane. Molecular Formula: C24H38O2Si. Molecular Weight: 386.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526858: 2-(2-(2-(2-Isopentoxy-ethoxy)-ethoxy)-ethoxy)-ethoxy)-ethanol

Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-[2-[2-(3-methylbutoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol. Molecular Formula: C15H32O6. Molecular Weight: 308.41. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529943: 1-[2-Methyl-(3-thienyldithio)]butan-2-one

Chemical compound data from PubChem database. IUPAC Name: 1-[(2-methylthiophen-3-yl)disulfanyl]butan-2-one. Molecular Formula: C9H12OS3. Molecular Weight: 232.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Hydrocortisone

Hydrocortisone is a prescription corticosteroid medication available as oral tablets in 5 mg, 10 mg, and 20 mg strengths. Manufactured by Aurobindo Pharma Limited, it works by reducing inflammation and suppressing the immune system, commonly used to treat conditions like allergies, arthritis, and adrenal insufficiency. This information was generated using AI and is provided for informational and research purposes only.
Patent AT-E400994-T1: [Translated] ELEMENTS AND WATER RETENTION PILLOWS, THEIR PRODUCTION PROCESSES AND APPLICATIONS

The invention concerns water retention elements comprising a water-permeable material adapted to absorb water and to gradually release absorbed water in a dry environment such as an insufficiently watered soil. The permeable material (2, 22) has interspersed gaps (3) for retaining water and is enclosed in an envelope much less permeable to water. The invention also concerns methods for making and using said water retention elements for humidifying crops or plants growing above a soil or basement which is dry or fast losing its moisture, and for producing a barrier between a cultivable fill soil and a porous basement unsuited for water retention.
COVID-19 Public Therapeutic Locator

<b>NOTE: This dataset is no longer updated as of 1/31/2024. Please use <a href="https://healthdata.gov/ASPR/COVID-19-Treatments/xkzp-zhs7/about_data">COVID-19 Treatments.</a></b>
<p>
Locations of publicly available COVID-19 Therapeutics. Dataset only includes locations for Paxlovid (oral antiviral), Lagevrio (oral antiviral), and outpatient Veklury (intravenous antiviral infusion). COVID-19 therapeutics require a prescription to obtain. Limitations: public contact information.
</p>
<p>
<b> To filter, click 'View Data' below, then 'Filter.' To save your view, click 'Save as,' and this configuration will be saved in your profile under 'My Assets.' <u>Please try not to publish dataset publicly, unless necessary.</b></u>
</p>

On 1/3/2022 - The following changes were made to this dataset.
- Dropped the Expected Deliver Date column - This was a derived field set to 3 days after the Last Order Date field.
- Added the following fields
   Last Date Delivered
   Total Courses
   Courses Available
   Courses Available Date

On 1/4/2022 - Added Geocoded Address

On 1/11/2022 - Added NPI - National Provider Identifier

On 2/18/2022 - Added new therapeutics, Bebtelovimab & Sotrovimab.

On 3/16/2022 - Dropped the following columns
      - last_order_date
      - last_date_delivered
      - total_courses
      - courses_available_date
   Added the following columns
      - facility_id
      - last_report_date
      - grantee_code
      - provider_pin
      - state_provider_pin

On 3/31/2022 - Dropped the following columns
      - facility_id
      - grantee_code
      - provider_pin
      - state_provider_pin
   Added the following columns
      - provider_status
      - provider_note
Histometric data obtained by in vivo confocal laser scanning microscopy in patients with systemic sclerosis

Background
          It would be a benefit if time-saving, non-invasive methods could give hints for diagnosing systemic sclerosis. To investigate the skin of patients with systemic sclerosis using confocal laser scanning microscopy in vivo and to develop histometric parameters to describe characteristic cutaneous changes of systemic sclerosis observed by this new technique, we conducted an exploratory study.
        
        
          Materials and Methods
          Fifteen patients with systemic sclerosis treated with extracorporal photopheresis were compared with 15 healthy volunteers and 10 patients with other disorders also treated with extracorporal photopheresis. All subjects were investigated using confocal laser scanning microscopy in vivo.
        
        
          Results
          Micromorphologic characteristics of skin of patients with systemic sclerosis and measuring parameters for melanisation, epidermal hypotrophy, and fibrosis for dislocation of capillaries by collagen deposits in the papillary dermis were evaluated. An interesting finding was an increased thickness of the tissue in the dermal papillae superior to the first dermal papilla vessel. It was also possible to reproduce characteristic histologic features by confocal laser scanning microscopy in vivo. Histometric parameters for fibrosis and vascular features developed in this study showed significant differences in patients with systemic sclerosis compared to controls.
        
        
          Conclusions
          Although the predominant histopathological features in systemic sclerosis are findings of the reticular dermis and the subcutis, and in histopathological investigation the epidermis seems to remain unaffected by the disease, we have demonstrate some characteristic differences in the epidermis and papillary dermis by confocal laser scanning microscopy in vivo. Some of them have not been described so far. However, to use this technique as a tool for diagnosis and/or staging of systemic sclerosis, further studies are needed investigating the sensitivity and specificity of the histometric parameters developed in this study.
COVID-19 State Profile Report - Kentucky

<b>After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.
Data about COVID-19 will continue to be updated at <a href='https://covid.cdc.gov/covid-data-tracker/#datatracker-home' >CDC’s COVID Data Tracker</a>.
 </b>

<p>
The State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.
 </p>

It is a weekly snapshot in time that:
<ul>
<li>Focuses on recent outcomes in the last seven days and changes relative to the month prior</li>
<li>Provides additional contextual information at the county level for each state, and includes national level information</li>
<li>Supports rapid visual interpretation of results with color thresholds</li>
</ul>
Patient attitudes toward using computers to improve health services delivery

Background
          The aim of this study was to examine the acceptability of point of care computerized prompts to improve health services delivery among a sample of primary care patients.
        
        
          Methods
          Primary data collection. Cross-sectional survey. Patients were surveyed after their visit with a primary care provider. Data were obtained from patients of ten community-based primary care practices in the spring of 2001.
        
        
          Results
          Almost all patients reported that they would support using a computer before each visit to prompt their doctor to: "do health screening tests" (92%), "counsel about health behaviors (like diet and exercise)" (92%) and "change treatments for health conditions" (86%). In multivariate testing, the only variable that was associated with acceptability of the point of care computerized prompts was patient's confidence in their ability to answer questions about their health using a computer (beta = 0.39, p = .001). Concerns about data security were expressed by 36.3% of subjects, but were not related to acceptability of the prompts.
        
        
          Conclusions
          Support for using computers to generate point of care prompts to improve quality-oriented processes of care was high in our sample, but may be contingent on patients feeling familiar with their personal medical history.
Expression of interleukin-18 receptor in fibroblast-like synoviocytes

An excess of the proinflammatory substance IL-18 is present in joints of patients with rheumatoid arthritis (RA), and expression of IL-18 receptor (IL-18R) regulates IL-18 bioactivity in various cell types. We examined the expression of IL-18R α-chain and β-chain and the biologic effects of IL-18 in fibroblast-like synoviocytes (FLS) after long-term culture. The presence of both IL-18R chains was a prerequisite for IL-18 signal transduction in FLS. However, all FLS cultures studied were either resistant or barely responsive to IL-18 stimulation as regards cell proliferation, expression of adhesion molecules ICAM-1 and vascular cell adhesion molecule (VCAM)-1, and the release of interstitial collagenase and stromelysin, IL-6 and IL-8, prostaglandin E2, or nitric oxide. We conclude that the presence of macrophages or IL-18R+ T cells that can respond directly to IL-18 is essential for the proinflammatory effects of IL-18 in synovitis in RA.
Compound 527737: Propanoic acid, 3-bromo-2-chloro, propyl ester

Chemical compound data from PubChem database. IUPAC Name: propyl 3-bromo-2-chloropropanoate. Molecular Formula: C6H10BrClO2. Molecular Weight: 229.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Trihexyphenidyl hydrochloride

Trihexyphenidyl Hydrochloride is a prescription medication available as oral tablets in 2mg and 5mg strengths. It's used to treat symptoms of Parkinson's disease and certain movement disorders caused by other medications. Manufactured by Bionpharma Inc. and Natco Pharma Limited under FDA application ANDA091630. This information was generated using AI and is provided for informational and research purposes only.
2010 CMHS Uniform Reporting System (URS) Output Tables for Rhode Island

Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.
AFCARS Report #22

This report provides preliminary estimates of Adoption and Foster Care Analysis and Reporting System (AFCARS) data for FY 2014. As states are permitted to resubmit AFCARS data, the estimates may change over time. This report reflects all AFCARS data received as of July 9, 2015 related to AFCARS reporting periods through September 30, 2014.

Metadata-only record linking to the original dataset. Open original dataset below.
Butalbital, acetaminophen, and caffeine

Butalbital, Acetaminophen, and Caffeine is a prescription capsule containing 300mg acetaminophen (pain reliever), 50mg butalbital (sedative for muscle relaxation), and 40mg caffeine (stimulant). It's used to treat tension headaches and is a controlled substance (Schedule III). Manufactured by Taro Pharmaceuticals U.S.A., Inc. This information was generated using AI and is provided for informational and research purposes only.
The clinical and molecular spectrum of galactosemia in patients from the Cape Town region of South Africa

Background
          The objective of this study was to document the clinical, laboratory and genetic features of galactosemia in patients from the Cape Town metropolitan region.
        
        
          Methods
          Diagnoses were based on thin layer chromatography for galactosuria/galactosemia and assays of erythrocyte galactose-1-phosphate uridyltransferase (GALT) and galactokinase activities. Patients were screened for the common S135L and Q188R transferase gene mutations, using PCR-based assays. Screening for the S135L mutation in black newborns was used to estimate the carrier rate for galactosemia in black South Africans.
        
        
          Results
          A positive diagnosis of galactosemia was made in 17 patients between the years 1980 to 2001. All had very low or absent galactose-1-phosphate uridyltransferase (GALT) activity, and normal galactokinase levels. The mean age at diagnosis was 5.1 months (range 4 days to 6.5 months). A review of 9 patients showed that hepatomegaly (9/9), and splenomegaly, failure to thrive, developmental delay, bilateral cataracts (6/9) were the most frequent features at diagnosis. Six had conjugated hyperbilirubinemia. Four experienced invasive E. coli infection before diagnosis. Ten patients were submitted to DNA analysis. All 4 black patients and 2 of mixed extraction were homozygous for the S135L allele, while all 3 white patients were homozygous for the Q188R allele. The remaining patient of mixed extraction was heterozygous for the Q188R allele. The estimated carrier frequency of the S135L mutation in 725 healthy black newborns was 1/60.
        
        
          Conclusions
          In the absence of newborn screening the delay in diagnosis is most often unacceptably long. Also, carrier frequency data predict a galactosemia incidence of approximately 1/14 400 for black newborns in the Cape Metropole, which is much higher than the current detection rate. It is thus likely that many patients go undetected.
Compound 528013: 4-Pentenyl 3,5-dinitrobenzoate

Chemical compound data from PubChem database. IUPAC Name: pent-4-enyl 3,5-dinitrobenzoate. Molecular Formula: C12H12N2O6. Molecular Weight: 280.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 526342: 2-Bromo-1,3,7,8-tetrachlorodibenzo-p-dioxin

Chemical compound data from PubChem database. IUPAC Name: 2-bromo-1,3,7,8-tetrachlorodibenzo-p-dioxin. Molecular Formula: C12H3BrCl4O2. Molecular Weight: 400.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Alaska (AK)

This report presents estimates for measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Alaska for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Compound 529139: Ethyl (2E)-(phenylhydrazono)(4-toluidino)ethanoate

Chemical compound data from PubChem database. IUPAC Name: N,N-bis(trimethylsilyl)decan-1-amine. Molecular Formula: C16H39NSi2. Molecular Weight: 301.66. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.